ClinicalTrials.gg

Program

Hyaluronic Acid

Also written as “sodium hyaluronate 0.18%”, “Sodium hyaluronate” and “sodium hyaluronate”.

Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Osteoarthritis · Gingivitis · Keratoconjunctivitis Sicca, led by 10 companies.

Furthest: phase 4, since Jan 7, 202117 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratorios Sophia S.A de C.V.40 open or runningphase 4since Jan 7, 2021Sep 4, 2019none ahead
AbbVie30 open or runningphase 4since Sep 25, 2008Sep 25, 2008none ahead
Sanofi30 open or runningphase 4since Aug 12, 2005Aug 12, 2005none ahead
Daiichi Sankyo10 open or runningphase 3since May 23, 2006May 23, 2006none ahead
IBSA Institut Biochimique11 open or runningphase 3since Sep 9, 2026Sep 9, 2026Jun 30, 2027phase 3 · NCT07819461
KLSMC Stem Cells10 open or runningphase 2since Mar 24, 2017Mar 24, 2017none ahead
Kunming Baker Norton Pharmaceutical Sales10 open or runningphase 4since Jun 27, 2016Jun 27, 2016none ahead
Lantibio10 open or runningphase 3since Jan 11, 2008Jan 11, 2008none ahead
Liquidia Technologies10 open or runningphase 1since Nov 22, 2016Nov 22, 2016none ahead
TRB Chemedica10 open or runningphase 2since Dec 23, 2010Dec 23, 2010none ahead

Also a collaborator on its studies: Premier Research Group and River Plate Biotechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Aug 12, 2005.

  1. Sep 14, 2006Phase 3 study in Osteoarthritis of ShoulderSanofi · NCT00377624 · 602 enrolled · United States
  2. Jan 11, 2008Lantibio's first study: phase 3 study in Dry Eye SyndromesNew to LantibioLantibio · NCT00599716 · 300 enrolled · United States
  3. Sep 25, 2008AbbVie's first study: phase 4 study in Dry Eye SyndromesNew to AbbVieAbbVie · NCT00761202 · 50 enrolled · United Kingdom
  4. Jan 21, 2009Phase 4 study in OsteoarthritisSanofi · NCT00830830 · 40 enrolled · United States
  5. Jul 10, 2009Phase 4 study in Dry Eye SyndromesAbbVie · NCT00938704 · 71 enrolled · Germany
  6. Dec 23, 2010TRB Chemedica's first study: phase 2 study in Osteoarthritis, KneeNew to TRB ChemedicaTRB Chemedica · NCT01267214 · 40 enrolled · Thailand
  7. Apr 16, 2014Phase 4 study in Dry Eye SyndromesAbbVie · NCT02117687 · 80 enrolled · France, United Kingdom
  8. Jun 27, 2016Kunming Baker Norton Pharmaceutical Sales's first study: phase 4 study in Osteoarthritis, KneeNew to Kunming Baker Norton Pharmaceutical SalesKunming Baker Norton Pharmaceutical Sales · NCT02826031 · 300 enrolled · China
  9. Nov 22, 2016Liquidia Technologies's first study: phase 1 study in Acute PainNew to Liquidia TechnologiesLiquidia Technologies · NCT02982889 · 29 enrolled · Denmark
  10. Mar 24, 2017KLSMC Stem Cells's first study: phase 2 study in Articular Cartilage Disorder of KneeNew to KLSMC Stem CellsKLSMC Stem Cells · NCT03101163 · 120 enrolled · United States, Malaysia
  11. Sep 4, 2019Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in Dry Eye SyndromesNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT04081610 · 34 enrolled · Mexico
  12. Jan 7, 2021Phase 2 study in Dry Eye SyndromesLaboratorios Sophia S.A de C.V. · NCT04704531 · 141 enrolled · Mexico
  13. Jan 7, 20212 phase 4 studiesLaboratorios Sophia S.A de C.V. · NCT04704518, NCT04702776
  14. Sep 9, 2026IBSA Institut Biochimique's first study: phase 3 study in Osteoarthritis, KneeNew to IBSA Institut BiochimiqueIBSA Institut Biochimique · NCT07819461 · 704 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Osteoarthritis, KneeIBSA Institut Biochimique · NCT07819461

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07819461Osteoarthritis, Knee3Not yet recruitingIBSA Institut BiochimiqueJun 30, 2027704
NCT04704531Dry Eye Syndromes · Mexico2CompletedLaboratorios Sophia S.A de C.V.Jun 8, 2022141
NCT04704518Photorefractive Keratectomy · Mexico4CompletedLaboratorios Sophia S.A de C.V.Dec 22, 202396
NCT04702776Dry Eye Syndromes · Mexico4CompletedLaboratorios Sophia S.A de C.V.May 15, 2023182
NCT04081610Dry Eye Syndromes · Mexico1CompletedLaboratorios Sophia S.A de C.V.Oct 23, 201934
NCT03101163Articular Cartilage Disorder of Knee · United States, Malaysia2CompletedKLSMC Stem CellsJul 2022120
NCT02982889Acute Pain · Denmark1CompletedLiquidia TechnologiesMar 23, 201729
NCT02826031Osteoarthritis, Knee · China4UNKNOWNKunming Baker Norton Pharmaceutical SalesOct 2017300
NCT02117687Dry Eye Syndromes · France, United Kingdom4CompletedAbbVieJan 27, 201580
NCT01267214Osteoarthritis, Knee · Thailand2CompletedTRB ChemedicaFeb 201040
NCT00938704Dry Eye Syndromes · Germany4CompletedAbbVieJun 200971
NCT00830830Osteoarthritis · United States4CompletedSanofi40
NCT00761202Dry Eye Syndromes · United Kingdom4CompletedAbbVieJun 200850
NCT00599716Dry Eye Syndromes · United States3CompletedLantibioApr 2008300
NCT00377624Osteoarthritis of Shoulder · United States3CompletedSanofi602
NCT00330135Osteoarthritis, Hip · France3TerminatedDaiichi SankyoMar 200785
NCT00130468Osteoarthritis · United States4CompletedSanofi150

How it is read

Names in the registry

  • “sodium hyaluronate 0.18%”, 2 entries
  • “Sodium hyaluronate”, 2 entries
  • “sodium hyaluronate”, 2 entries
  • “Hyalgan (sodium hyaluronate)”, 2 entries
  • “Sodium hyaluronate solution - 3.36%”, 1 entry

Codes read as this program: PRO037.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.